TEST:

LymphoTrack® Dx IGH Assay

The correlation coefficients (r) of MRD levels were 0.831 between CM-IGH and LT-IGH, 0.702 between CM-IGH and MFC, and 0.776 between LT-IGH and MFC. The CM-IGH assay demonstrates substantial concordance with LT-IGH and MFC in detecting MRD in pediatric patients with B-ALL, highlighting the complementary value of IGH clonality assays and MFC.

All patients with Philadelphia chromosomes-positive ALL received imatinib concomitantly with chemotherapy...Detection of IgH clonality after second cycle of chemotherapy correlates with inferior survival in B-ALL. Therefore, those patients should be considered for subsequent treatments, such as allogeneic stem cell transplantation or novel monoclonal antibody.

P=N/A, N=250, Completed, Invivoscribe, Inc. | Recruiting --> Completed | Trial completion date: Aug 2024 --> Nov 2024 | Trial primary completion date: Jun 2024 --> Nov 2024

Based on our experience, SHM status can be achieved by routine NGS testing. Our first-year mutated-versus-unmutated test results are reasonably close to what is reported in the literature, supporting the effectiveness of this assay. The majority (66.6%) of QNS samples were due to lack of evidence of clonality in CLL samples.

Samples derived from cases from both the experimental and the control arm, based respectively on ponatinib followed by blinatumomab and on a combination of imatinib and conventional chemotherapy. While some groups reported a higher predictive prognostic power of IG/TR monitoring, our findings do not confirm these data, also in view of the very low rate of relapses so far observed. Nevertheless, a double-hit strategy may be informative for MRD monitoring and possibly for the distinction between typical/lymphoid Ph+ ALL vs multilineage/CML-like Ph+ ALL.

Method : This study involved adult patients aged 19 or older with B-ALL, treated with modified hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and allogeneic hematopoietic stem cell transplant (allogeneic-HSCT) at Catholic Hematology Hospital from May 2022 to June 2024...Poor MRD response was defined as > 0.1%, and complete MRD response as < 0.001%, and poor MRD responders were treated with MRD-directed therapy using blinatumomab or next-generation tyrosine kinase inhibitors...Conclusion : Our data suggested all MRD detection methods showed acceptable power and good concordance rates, but the detection power was different between Ph-positive and Ph-negative ALL. We also suggested MRD-directed therapeutic strategies might predict the significant time point of MRD for the prediction of survival outcomes.

Figure 1. Circos plot depicts structural variants in ALL patient.

This study constitutes the first attempt at using NGS to assess the mutational status of the IGHV gene in Lebanese patients. Further investigation could help identify new subsets and classifications. Additional studies combining cytogenetic analysis and molecular testing may prove useful for a better understanding of the characteristics of CLL patients, leading to optimal personalized care.

This is the largest study conducted to date in Ireland, profiling risk status in this genetically homogenousnorthern European population. In this study almost one third of TE-MM patients in Ireland present with HRdisease as defined by MMProfilerâ„¢ and validated by independent FISH. The reasons for the high prevalence ofHR-MM at diagnosis is not clear and further in-depth genomic profiling is needed.

"Compared with NGF, NGS exhibits higher sensitivity and reproducibility in MRD detection and can be an effective strategy for MRD monitoring in Chinese MM patients."

P=N/A, N=250, Recruiting, Invivoscribe, Inc. | Not yet recruiting --> Recruiting

We continue to evaluate the clinical significance of SKY92 in combination with MRD testing as a superior prognostic repertoire of testing. These methods will improve risk stratification, and in future aid with risk-adapted therapy approaches.